Chapter 7

Economic evaluation of dabigatran for the treatment and secondary prevention of venous thromboembolism

Jelena Stevanović, Evgeni Dvořák, Bregt Kappelhoff, Maarten Voorhaar, Maarten J. Postma
Submitted manuscript.
ABSTRACT

Background: Dabigatran was proven to have similar effect on the recurrence of venous thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists (VKA). The aim of this study is to assess the cost-effectiveness (CE) of dabigatran for the treatment and secondary prevention in high risk patients of VTE compared to VKAs in the Dutch setting.

Methods: The previously published Markov model was modified and updated to assess the CE of dabigatran and VKAs for the treatment and secondary prevention in high risk patients of VTE from a societal perspective in the base-case analysis. The model was populated with efficacy and safety data from major dabigatran trials (i.e. RE-COVER, RECOVER II, RE-MEDY and RE-SONATE), Dutch specific costs, and utilities derived from dabigatran trials or other published literature. Univariate, probabilistic sensitivity and a number of scenario analyses on the impact of various decision-analytic settings (e.g. the perspective of analysis, use of anticoagulants only for treatment or only for secondary prevention) were tested on the incremental cost-effectiveness ratio (ICER).

Results: In the base-case analysis, patients on dabigatran gained an additional 0.583 discounted quality adjusted life years (QALYs) over a lifetime and savings of €1,996. Results of univariate sensitivity analysis were quite robust. The probability that dabigatran is cost-effective at a willingness-to-pay threshold of €20,000/QALY was 100%. Except for the scenario comparing the use of dabigatran and VKAs from the healthcare provider perspective and the one comparing dabigatran to placebo for the prevention of recurrent VTE in patients who are at equipoise for anticoagulation treatment where the ICERs for dabigatran compared to VKAs of €1,005 and €33,305 per QALY gained, respectively were estimated, other scenarios showed dabigatran was cost-saving.

Conclusion: From a societal perspective, dabigatran is likely to be a cost-effective or even cost-saving strategy for treatment and secondary prevention of VTE compared to VKAs in the Netherlands.
INTRODUCTION

Venous thromboembolism (VTE) can manifest as deep vein thrombosis (DVT) and/or pulmonary embolism (PE)(1). The health burden associated with VTE is mostly determined with the risk of a fatal PE and risk of considerable late morbidity associated with the development of post thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, recurrent DVT (rDVT) occurs in approximately 7% of patients per year and reaches to about one quarter to one third of patients within 8 years (2)(3). The health related quality of life (HRQoL) in VTE patients is also affected. For example, a Dutch study found distinctly lower HRQoL scores measured with SF-36 questionnaire in patients with PE compared to the general population on the subscales: social functioning, role emotional, general health, role physical and vitality (4).

In the Netherlands, the DVT incidence was estimated to approximately 16,000 to 20,000 cases per year (5). Though, the overall incidence of PE in the Netherlands is unknown, a survey among Dutch pulmonologists/internists indicated the incidence of suspected PE was 2.6 per 1,000 patients per year (2), while in general practice, 0.2 PEs per 1,000 patients were reported (6).

Both national and international guidelines recommend anticoagulation therapy as an effective measure to prevent thrombus propagation and recurrence in VTE patients (1,2). For the initial treatment phase of VTE, low-molecular-weight heparins (LMWHs) for at least 5 days combined with subsequent administration of vitamin K antagonists (VKAs; e.g. warfarin, acenocoumarol or phenprocoumon), or rivaroxaban are recommend. For the maintenance phase, the use of VKAs or rivaroxaban is recommended for at least three months (1,7). The need to continue anticoagulation should be re-assessed in patients based on individual patient risk-benefit balance every three months as there is no strong distinction between treatment and prevention phase (1,7).

VKAs present a highly effective anticoagulation treatment which use is limited by a narrow therapeutic range (international normalised ratio (INR) limits of 2.0 and 3.0) and several interactions with other drugs and food. To achieve the anticoagulant effect inside the required INR range, regular monitoring and dose-adjustment is required for treatment with VKAs. In the Dutch healthcare system, INR-monitoring is handled by thrombotic services or patient self-management. Though it is considered highly effective in the Netherlands, INR-monitoring also affects expenditures from both healthcare provider and societal perspective. In particular, next to the costs of material, labour, nurse visits, training and material for self-management that affect healthcare providers, there are various out-of-the pocket expenses (e.g. travel costs of patients) and productivity loss costs associated with monitoring visits that have an impact on a societal economic burden. Recently, in the RE-COVER and RE-COVER II trials, dabigatran, a novel oral anticoagulant (NOAC) was shown to have similar effect on VTE recurrence and a lower risk for clinically
relevant non-major bleeding (CRNMB) and for any bleeding compared to VKA (8,9). When administered for the extended treatment in patients with VTE who had completed at least three months of initial therapy, dabigatran was non-inferior in preventing rVTE events and showed a better safety profile than VKA (the RE-MEDY trial), but a significantly better efficacy in preventing rVTE and higher risk of bleedings than placebo (the RE-SONATE trial) (10).

Importantly, both health and economic consequences associated with the use of dabigatran compared to VKAs need to be considered when choosing the optimal treatment strategy. A formal pharmacoeconomic comparison of the two anticoagulant treatments should be conducted to account for all the relevant health consequences such as likelihood of rVTE, bleedings, PTS, CTEPH, death and other adverse events, as well as all relevant cost parameters including the costs of drugs, administration, INR-monitoring, event-related costs and various indirect costs.

The aim of this study is to assess the cost-effectiveness (CE) of dabigatran (300mg per day) for the treatment and secondary prevention in high risk patients of DVT and PE compared to VKAs for the Dutch situation.

METHODS

Decision model
The previously published Markov model was modified and updated to assess the CE of dabigatran and VKAs for the treatment and secondary prevention of DVT and PE in the Dutch setting. The health states included in the model were: index VTE, rVTE, major or clinically relevant bleeding (MCRB), CTEPH, PTS, other adverse events (i.e. myocardial infarction (MI), unstable angina (UA) and dyspepsia), off-treatment and death from other causes (Figure 1).

In the base-case, the use of dabigatran was compared to VKAs for up to 6 months of treatment followed by up to 18 months of secondary prevention in high risk patients. The flow of patients with an index VTE event through the Markov model is detailed elsewhere (11). Shortly, at the start of the simulation, a hypothetical cohort of 10,000 adult patients (mean age 54.7 years) for whom at least 6 months of anticoagulant therapy was considered appropriate entered the model following an index VTE (i.e. index DVT or index PE) event and received initial treatment with LMWHs followed by either dabigatran or VKAs. The duration of treatment with LMWHs was assumed to be 5 days in dabigatran treatment arm to follow the summaries of product characteristics (SCPs) for dabigatran, and 9 days in VKAs arm to simulate the treatment in RE-COVER trials. Patients in the index VTE state were exposed to the risk of rVTE, MCRB, CTEPH, PTS, other adverse events, treatment discontinuation and death from other causes. After the initial 6 months of treatment, patients who remained in the index health state were simulated to receive up
to 18 months of anticoagulants for the secondary prevention, reflecting patient profiles from the RE-MEDY trial (10).

*rVTE* could occur in any model cycle, however, the model was restricted to a maximum of two *rVTEs* (12). Furthermore, a distinction was made between different forms of *rVTE* (i.e. a fatal VTE, non-fatal PE, proximal DVT and distal DVT). After a first *rVTE*, patients from both treatment arms were assumed to stop the initial treatment and initiate or reinitiate a 6 months standard treatment course of LMWHs followed by VKAs.

For patients experiencing a *MCRB*, a distinction was made between an intracranial haemorrhage (ICH), other major bleed (MB), and a CRNMB. If ICH occurred, it could lead to permanent disability, death, or recovery. MBs were modelled to lead to death or recovery. Furthermore, it was assumed that patients can experience up to two major bleeds (ICH or MB) during the entire time they may spend on anticoagulation; one event could be experienced during treatment phase with study medication and one event during LMWHs/VKAs re-treatment (12). CRNMB could occur at every model cycle while on anticoagulation (12). After a MB or ICH, all patients were assumed to discontinue treatment altogether having no further risk of bleeding, but continuing to be exposed to a risk of *rVTE*.

In the model, all patients who experienced a first or recurrent PE (rPE) were at risk to develop *CTEPH*, while those with an index or *rDVT* were at risk of *PTS*.

*Other adverse events* of anticoagulant therapy captured by the model are UA, MI and dyspepsia. Patients with a non-fatal MI or UA could suffer from chronic ischemic heart disease (IHD), or recover.

During treatment or secondary prevention phases, all patients could discontinue treatment prior to reaching the maximum planned duration of treatment due to reasons other than *rVTE* or ICH/MB. If discontinuation occurs, patients move to *off-treatment* state where they continue to experience a risk of *rVTE*, but no further risk of bleeds. Finally, patients in any of the health states were at risk to *die from other causes*. Patient movement between health states was modeled using 1-month cycles for 60 years or until death.

The final outcome of the decision model is the incremental cost-effectiveness ratio (ICER) of dabigatran compared to VKAs. Quality-adjusted life-years (QALYs) and life-years (LYs) gained were estimated as a measure of effectiveness. All relevant costs reflect a societal perspective in the base-case analysis and are inflated, if necessary, to price year 2013 using the Dutch consumer price index (13). Future costs and health effects were discounted by 4% and 1.5% annually after the first year, according to the Dutch guidelines for pharmacoeconomic research (14).

**Transition probabilities**

In the base-case, to estimate the transition probabilities between the health states in the model during the treatment and prevention phase, data from a published meta-analysis of
Chapter 7

the RE-COVER and RE-COVER II trials (8)(9) and the RE-MEDY trial (10), respectively were used, similarly to the previously published Markov model (11).

In particular, the baseline probabilities of rVTE and MCRB were calculated from the observed incidence in VKA arm of the aforementioned trials. For the treatment phase, the incidences of rVTE and MCRB were log transformed with respect to time, to better reflect the occurrence pattern of these events in the trials. For the secondary prevention phase, the incidences were not varied with time. To calculate the probabilities of events while on dabigatran, the estimated treatment effect (hazard ratio (HR)) for each trial endpoint was applied to the risk in the VKA arm (Table 1).

Furthermore, the probabilities of having a fatal VTE, non-fatal PE, proximal DVT, or distal DVT, were based on the incidences of these events in the aforementioned trials, and they were modelled to be conditional on having a VTE event. Similarly, the probabilities of having an ICH, other MB, fatal MB (including ICH) or CRNMB were conditional on having a MCRB. The proportion of ICH leading to permanent disability was assumed to be 65.3% (15).

Beyond the duration of the anticoagulant treatment, the lifetime probability of rVTE was calculated from the assumed 10-year cumulative incidence of 39.9% (16), assuming a constant hazard. The risk of bleeding after treatment discontinuation was assumed at zero.

Probabilities of MI, UA and dyspepsia were estimated from the dabigatran trials (8)(9)(10). For the treatment followed by secondary prevention, probabilities of MI, fatal MI and UA were calculated as the sum of probabilities in the treatment and secondary prevention trials. Events were assumed to occur at a constant rate during the trial follow-up. For simplicity, events were assigned to occur at the midpoint (i.e., three months). Additionally, we assumed 14% of MIs and UAs would lead to IHD (17).

CTEPH rate for all patients in index PE was estimated to be 3.8% for two years (18). For patients experiencing non-fatal rPE events, the risk of CTEPH was applied monthly up to 2 years (18).

Published evidence suggests that mild PTS has little detrimental effect on HRQoL(6), therefore, the model included only severe PTS. For all patients in index DVT, the 5-year rate of PTS was estimated to be 8.1% at model start (19). A monthly probability of PTS subsequent to non-fatal rDVT events was applied up to 5 years (19). Finally, the probability of death due to other causes was obtained from Statistics Netherlands.
Table 1 Distribution and parameter limits for the transition probabilities in the model as used in the probabilistic sensitivity analysis.

<table>
<thead>
<tr>
<th>Clinical variable</th>
<th>Value</th>
<th>CI (95%)</th>
<th>Distribution</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of rVTE (baseline risk), treatment</td>
<td>2.43%</td>
<td>-</td>
<td>Beta (α=62, β=2492)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>Incidence of MCRB (baseline risk), treatment</td>
<td>7.68%</td>
<td>-</td>
<td>Beta (α=189, β=2273)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>Treatment effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rVTE, dabigatran vs VKA (HR)</td>
<td>1.09</td>
<td>0.77 – 1.54</td>
<td>Normal (log scale)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>MCRB, dabigatran vs VKA (HR)</td>
<td>0.56</td>
<td>0.45 – 0.71</td>
<td>Normal (log scale)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>Secondary prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rVTE, dabigatran vs VKA (HR)</td>
<td>1.44</td>
<td>0.78 – 2.64</td>
<td>Normal (log scale)</td>
<td>(10)</td>
</tr>
<tr>
<td>rVTE, dabigatran vs placebo (HR)</td>
<td>0.08</td>
<td>0.02 – 0.25</td>
<td>Normal (log scale)</td>
<td>(10)</td>
</tr>
<tr>
<td>MCRB, dabigatran vs VKA (HR)</td>
<td>0.55</td>
<td>0.41 – 0.72</td>
<td>Normal (log scale)</td>
<td>(10)</td>
</tr>
<tr>
<td>MCRB, dabigatran vs placebo (HR)</td>
<td>2.69</td>
<td>1.43 – 5.07</td>
<td>Normal (log scale)</td>
<td>(10)</td>
</tr>
<tr>
<td>Type of recurrent VTE events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabigatran</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal PE</td>
<td>33.8%</td>
<td></td>
<td>Beta (α=23, β=45)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>Proximal DVT</td>
<td>63.2%</td>
<td></td>
<td>Beta (α=43, β=25)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>VTE-related death</td>
<td>2.9%</td>
<td></td>
<td>Beta (α=2, β=66)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>Distal DVT</td>
<td>0.0%</td>
<td></td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>VKA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal PE</td>
<td>33.9%</td>
<td></td>
<td>Beta (α=21, β=41)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>Proximal DVT</td>
<td>61.3%</td>
<td></td>
<td>Beta (α=38, β=24)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>VTE-related death</td>
<td>4.8%</td>
<td></td>
<td>Beta (α=3, β=59)</td>
<td>(8,9)</td>
</tr>
<tr>
<td>Distal DVT</td>
<td>0.0%</td>
<td></td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>Secondary prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabigatran (RE-MEDY trial)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal PE</td>
<td>34.6%</td>
<td></td>
<td>Beta (α=9, β=17)</td>
<td>(10)</td>
</tr>
<tr>
<td>Proximal DVT</td>
<td>61.5%</td>
<td></td>
<td>Beta (α=16, β=10)</td>
<td>(10)</td>
</tr>
<tr>
<td>VTE-related death</td>
<td>3.8%</td>
<td></td>
<td>Beta (α=1, β=25)</td>
<td>(10)</td>
</tr>
<tr>
<td>Distal DVT</td>
<td>0.0%</td>
<td></td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>Dabigatran (RE-SONATE trial)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal PE</td>
<td>33.3%</td>
<td></td>
<td>Beta (α=1, β=2)</td>
<td>(10)</td>
</tr>
<tr>
<td>Proximal DVT</td>
<td>66.7%</td>
<td></td>
<td>Beta (α=2, β=1)</td>
<td>(10)</td>
</tr>
<tr>
<td>VTE-related death</td>
<td>0.0%</td>
<td></td>
<td>Beta (α=0.5, β=4)</td>
<td>(10)</td>
</tr>
<tr>
<td>Distal DVT</td>
<td>0.0%</td>
<td></td>
<td>Fixed</td>
<td></td>
</tr>
<tr>
<td>VKA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal PE</td>
<td>22.2%</td>
<td></td>
<td>Beta (α=4, β=14)</td>
<td>(10)</td>
</tr>
<tr>
<td>Proximal DVT</td>
<td>72.2%</td>
<td></td>
<td>Beta (α=13, β=5)</td>
<td>(10)</td>
</tr>
<tr>
<td>VTE-related death</td>
<td>5.6%</td>
<td></td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>Distal DVT</td>
<td>0.0%</td>
<td></td>
<td>Beta (α=1, β=17)</td>
<td>(10)</td>
</tr>
<tr>
<td>After therapy discontinuation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal PE</td>
<td>23.3%</td>
<td></td>
<td>Beta (α=87, β=286)</td>
<td>(16)</td>
</tr>
<tr>
<td>Clinical variable</td>
<td>Value</td>
<td>CI (95%)</td>
<td>Distribution</td>
<td>Reference</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------</td>
<td>----------</td>
<td>--------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Proximal DVT</td>
<td>65.1%</td>
<td>Beta (α=243, β=130)</td>
<td>(16)</td>
<td></td>
</tr>
<tr>
<td>VTE-related death</td>
<td>11.5%</td>
<td>Beta (α=43, β=330)</td>
<td>(16)</td>
<td></td>
</tr>
<tr>
<td>Distal DVT</td>
<td>0.0%</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of bleeding events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabigatran</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>1.8%</td>
<td>Beta (α=2, β=107)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>Other MB</td>
<td>20.2%</td>
<td>Beta (α=22, β=87)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>Fatal MB</td>
<td>4.2%</td>
<td>Beta (α=1, β=23)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>CRNMB</td>
<td>78.0%</td>
<td>Beta (α=85, β=24)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>VKA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>2.1%</td>
<td>Beta (α=4, β=185)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>Other MB</td>
<td>19.0%</td>
<td>Beta (α=36, β=153)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>Fatal MB</td>
<td>5.0%</td>
<td>Beta (α=2, β=38)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>CRNMB</td>
<td>78.8%</td>
<td>Beta (α=149, β=40)</td>
<td>(8,9)</td>
<td></td>
</tr>
<tr>
<td>Secondary prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabigatran (RE-MEDY)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>2.5%</td>
<td>Beta (α=2, β=78)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Other MB</td>
<td>13.8%</td>
<td>Beta (α=11, β=69)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Fatal MB</td>
<td>0.0%</td>
<td>Fixed</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>CRNMB</td>
<td>83.8%</td>
<td>Beta (α=67, β=13)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Dabigatran (RE-SONATE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>0.0%</td>
<td>Fixed</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Other MBE</td>
<td>5.6%</td>
<td>Beta (α=2, β=34)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Fatal MBE</td>
<td>0.0%</td>
<td>Fixed</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>CRNMB</td>
<td>94.4%</td>
<td>n/a</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>VKA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>2.8%</td>
<td>Beta (α=4, β=141)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Other MB</td>
<td>14.5%</td>
<td>Beta (α=21, β=124)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Fatal MB</td>
<td>4.0%</td>
<td>Beta (α=1, β=24)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>CRNMB</td>
<td>82.8%</td>
<td>Beta (α=120, β=25)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Other probabilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disabled from ICH</td>
<td>65.3%</td>
<td>Beta (α=90.8, β=48.2)</td>
<td>(15)</td>
<td></td>
</tr>
<tr>
<td>Probability of IHD after MI and UA</td>
<td>14%</td>
<td>Beta (α=19, β=116)</td>
<td>(17)</td>
<td></td>
</tr>
<tr>
<td>Cumulative incidence of CTEPH at 2 years in PE patients</td>
<td>3.8%</td>
<td>Beta (α=7, β=184)</td>
<td>(18)</td>
<td></td>
</tr>
<tr>
<td>Probability of CTEPH (per cycle)</td>
<td>0.16%</td>
<td></td>
<td></td>
<td>(18)</td>
</tr>
<tr>
<td>5 years cumulative incidence of severe PTS</td>
<td>8.1%</td>
<td>Beta (α=43, β=485)</td>
<td>(19)</td>
<td></td>
</tr>
<tr>
<td>Probability of severe PTS (per cycle)</td>
<td>0.14%</td>
<td></td>
<td></td>
<td>(19)</td>
</tr>
<tr>
<td>rVTE after therapy discontinuation</td>
<td>39.90%</td>
<td>Normal (SE=0.02)</td>
<td>(16)</td>
<td></td>
</tr>
<tr>
<td>Discontinuation probabilities (per cycle)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabigatran</td>
<td>2.09%</td>
<td>Fixed</td>
<td>(8,9)</td>
<td></td>
</tr>
</tbody>
</table>
### Table 2 Utility parameters applied in the model.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Distribution</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 18-24 years (weight for males, females)</td>
<td>0.976, 0.925</td>
<td>Fixed</td>
<td>(20)</td>
</tr>
<tr>
<td>Age 25-34 years (weight for males, females)</td>
<td>0.945, 0.907</td>
<td>Fixed</td>
<td>(20)</td>
</tr>
<tr>
<td>Age 35-44 years (weight for males, females)</td>
<td>0.953, 0.917</td>
<td>Fixed</td>
<td>(20)</td>
</tr>
<tr>
<td>Age 45-54 years (weight for males, females)</td>
<td>0.902, 0.877</td>
<td>Fixed</td>
<td>(20)</td>
</tr>
<tr>
<td>Age 55-64 years (weight for males, females)</td>
<td>0.913, 0.866</td>
<td>Fixed</td>
<td>(20)</td>
</tr>
<tr>
<td>Age 65-74 years (weight for males, females)</td>
<td>0.878, 0.894</td>
<td>Fixed</td>
<td>(20)</td>
</tr>
<tr>
<td>Age ≥ 75 years (weight for males, females)</td>
<td>0.910, 0.787</td>
<td>Fixed</td>
<td>(20)</td>
</tr>
<tr>
<td>Disutility during active VKA treatment</td>
<td>0.012</td>
<td>Gamma (α=28.66, β=0.0004)</td>
<td>(25)</td>
</tr>
<tr>
<td>Disutility of index and recurrent DVT</td>
<td>0.250</td>
<td>Normal (SE=0.0054)*</td>
<td>(11)</td>
</tr>
<tr>
<td>Disutility of index and recurrent PE</td>
<td>0.250</td>
<td>Normal (SE=0.0052)*</td>
<td>(11)</td>
</tr>
<tr>
<td>Disutility of ICH or other MB</td>
<td>0.130</td>
<td>Gamma (α=100, β=0.001)</td>
<td>(11)</td>
</tr>
<tr>
<td>Disutility of disabled from ICH</td>
<td>0.380</td>
<td>Gamma (α=16, β=0.024)</td>
<td>(21)</td>
</tr>
<tr>
<td>Disutility of CRNMB</td>
<td>0.040</td>
<td>Gamma (α=100, β=0.0004)</td>
<td>(11)</td>
</tr>
<tr>
<td>Disutility of MI</td>
<td>0.063</td>
<td>Gamma (α=22.57, β=0.003)</td>
<td>(22)</td>
</tr>
<tr>
<td>Disutility of Angina</td>
<td>0.085</td>
<td>Gamma (α=40.40, β=0.002)</td>
<td>(22)</td>
</tr>
<tr>
<td>Disutility of Dyspepsia</td>
<td>0.040</td>
<td>Gamma (α=16, β=0.003)</td>
<td>(23)</td>
</tr>
<tr>
<td>Disutility of CTEPH</td>
<td>0.440</td>
<td>Gamma (α=16, β=0.028)</td>
<td>(24)</td>
</tr>
<tr>
<td>Disutility of severe PTS</td>
<td>0.070</td>
<td>Gamma (α=39.22, β=0.002)</td>
<td>(6)</td>
</tr>
</tbody>
</table>

CRNMB = clinically relevant non-major bleed event; DVT = deep vein thrombosis; ICH = intracranial haemorrhage; MB = major bleed; MI = myocardial infarction; PE = pulmonary embolism; CTEPH = chronic thromboembolic pulmonary hypertension; PTS = post thrombotic syndrome.

* Change in mean from baseline to 3 months. In the probabilistic analysis, the mean baseline and 3-month value were individually sampled from normal distributions defined by the mean and standard error (standard error was calculated from the standard deviation and N) and the difference calculated for each simulation.

* Variance was not reported; the standard error is assumed to be 25% of the mean.

* The duration of disutility was assumed to be 6 weeks similarly to the previously published study.

* A disutility is applied in the month of the event. Specifically, the duration of the impact of UA and MI on HRQoL was assumed to be 3 months.

* The disutility applied is assumed to last for the duration of treatment.

* A disutility is applied for the remaining lifetime.
Utilities

Table 2 summarises the utilities used in the model. Patients were assigned baseline age- and gender-specific utilities derived from the general Dutch population (20). These estimates formed the baseline from which the utility decrements associated with VTE, bleeding and other adverse events were subtracted.

Utility decrements associated index and rVTE, MB and CRNMB were based on a meta-analysis of EQ-5D data collected in the RE-COVER and RE-COVER II trials and applied in the model similarly to the previously published study (11).

Utility decrements following the occurrence of other adverse events (i.e. MI, UA, dyspepsia, disabled from ICH, CTEPH, and severe PTS) were derived from the published studies and applied additively for a specific time interval in the model (21)(22)(23)(6)(24). Finally, utility decrements reflecting the use of VKA were applied (25).

Costs

In the base-case analysis, all costs were collected from a societal perspective, therefore, both direct (inside and outside healthcare) and indirect costs were included (Table 3). Direct costs inside healthcare included the costs related to: drugs, visits to general practitioner (GP), administration, INR-monitoring, event-related resources. Costs of dabigatran, defined as price per defined daily dose (2x 150mg), VKAs and LMWHs were taken from the official Dutch price list (Z-index) (26). Importantly, the price of dabigatran extracted from Z-index is established for other registered indications of dabigatran in the Netherlands (i.e. prevention of VTE in patients who have undergone elective total hip replacement surgery or total knee replacement surgery, and prevention of stroke and systemic embolism in non-valvular atrial fibrillation). Acenocumarol and phenprocoumon are the only VKAs registered in the Netherlands, therefore, the cost of VKAs was estimated as a weighted average cost of those drugs based on their usage in the Netherlands (80%:20%, respectively)(27). The cost of LMWHs was assumed as a weighted average cost of enoxaparin, dalteparin, tinzaparin and nadroparin (26). All treatment alternatives were assumed to have a cost of one initial GP visit in the first month and one follow up visit in the 4th month of a treatment.

The cost of administration of LMWHs was estimated to reflect the costs of administration in hospital and at home. For patients receiving LMWHs in hospital, the costs of administration was adjusted for the percentage of patients and time they spent being hospitalized for DVT and for PE (28). The costs of administration at home accounted for the costs of self-injection and costs for patients requiring a nurse visit for injection (Table 3)(28,29).

The costs of INR-monitoring reflected the costs of monitoring handled by thrombotic services and costs for patient self-management (Table 3). In the Netherlands, self-management is applied by 14.9% of patients on treatment with VKAs. Therefore, the costs of initial training for self-management and monthly follow up costs associated with the
rental of equipment were applied for this patient population (Table 3). Resource use associated with INR-monitoring at thrombotic services (i.e. number of visits) was based on the data from the RECOVER trials (8)(9). In particular, in the first month of a treatment, the cost of INR-monitoring by thrombotic services reflected the costs of 4.3 visits to thrombotic services. In follow up months (2
²
 and 6
²
th month), the cost of 1.9 visits per month was assumed (8)(9). For the application of VKAs longer than 6 months (i.e. secondary prevention phase), the costs of INR-monitoring by thrombotic services reflected the cost of 1.5 visits per month (8)(9). Moreover, direct costs outside healthcare (i.e. travel costs) were attributed to the nurse visits for injection of LMWHs. Acute care costs associated with clinical events (e.g. DVT, PE, ICH, other MB, CRNMB, PTS, CTEPH, MI, UA, and dyspepsia) were adopted from previous costing studies conducted in the Netherlands. Patients surviving acute ICH, MI, PTS and CTEPH were assigned with long-term maintenance costs.

Indirect costs outside healthcare included: productivity loss costs, caregiver time costs for patients experiencing ICH and travel costs for the visits of patients to thrombotic services. A 2-hour productivity loss costs were assumed for all INR-monitoring visits to thrombotic services and all GP-related visits. Additionally, productivity loss costs associated with hospitalizations due to DVT (0.63 days), PE (7 days) and MI (5.6 days) were included. The number of productivity loss hours for each of the aforementioned hospitalizations was estimated in order to account for regular working hours (8 hours per day) and was corrected for the weekends (14,30).

Table 3 Cost parameters applied in the model.

<table>
<thead>
<tr>
<th>Cost parameters</th>
<th>Average cost (2013, €)</th>
<th>cost</th>
<th>Range</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication, administration and monitoring costs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VKA (daily)</td>
<td>0.04</td>
<td>0.03-0.05</td>
<td>(26)</td>
<td></td>
</tr>
<tr>
<td>Dabigatran (daily)</td>
<td>2.30</td>
<td>Fixed</td>
<td></td>
<td>(26)</td>
</tr>
<tr>
<td>LMWH (daily)</td>
<td>10.65</td>
<td>7.99-13.31</td>
<td>(26)</td>
<td></td>
</tr>
<tr>
<td>LMWH at home, self-injection (one-off training)</td>
<td>16.77</td>
<td>9.59-25.93</td>
<td>(29)</td>
<td></td>
</tr>
<tr>
<td>LMWH at home, nurse injection (per day after discharge)</td>
<td>17.50</td>
<td>10.00-27.05</td>
<td>(29)</td>
<td></td>
</tr>
<tr>
<td>LMWH, administration in clinic (per day after discharge) incl. travel costs</td>
<td>16.54</td>
<td>9.45-25.57</td>
<td>(29)</td>
<td></td>
</tr>
<tr>
<td>LMWH at home, self-injection (domiciliary care)</td>
<td>6.74</td>
<td>3.85-10.43</td>
<td>(29)</td>
<td></td>
</tr>
<tr>
<td>GP visit</td>
<td>30.54</td>
<td>17.46-47.22</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td>INR-control self-management initial monthly cost</td>
<td>90.46</td>
<td>51.71-139.88</td>
<td>(14,31)</td>
<td></td>
</tr>
<tr>
<td>INR-control cost incl. travel costs (per visit) b</td>
<td>12.54</td>
<td>7.17-19.38</td>
<td>(14,31)</td>
<td></td>
</tr>
<tr>
<td>INR-control self-management (monthly)</td>
<td>12.29</td>
<td>7.03-19.01</td>
<td>(14,31)</td>
<td></td>
</tr>
</tbody>
</table>

Events costs
## Cost parameters

<table>
<thead>
<tr>
<th>Cost parameters</th>
<th>Average (2013, €)</th>
<th>Cost</th>
<th>Range</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVT</td>
<td>1,187.23</td>
<td>679-1,836</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>PE</td>
<td>4,221.01</td>
<td>2,413-6,527</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>ER visit</td>
<td>167.28</td>
<td>96-259</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>Chest x-ray</td>
<td>156.15</td>
<td>89-241</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>Electrocardiogram</td>
<td>30</td>
<td>17-46</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>Acute ICH</td>
<td>32,754</td>
<td>18,722-50,646</td>
<td>(21)</td>
<td></td>
</tr>
<tr>
<td>ICH direct mild (annually)</td>
<td>2,367.97</td>
<td>1,354-3,662</td>
<td>(21)</td>
<td></td>
</tr>
<tr>
<td>ICH direct moderate (annually)</td>
<td>18,268</td>
<td>10,442-28,247</td>
<td>(21)</td>
<td></td>
</tr>
<tr>
<td>ICH direct severe (annually)</td>
<td>23,353</td>
<td>13,348-36,110</td>
<td>(21)</td>
<td></td>
</tr>
<tr>
<td>MB</td>
<td>4,969</td>
<td>2,840-7,683</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>CRNMB</td>
<td>31</td>
<td>17-47</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td>PTS (year 1)</td>
<td>25,073</td>
<td>14,331-38,769</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>PTS (year 2)</td>
<td>61</td>
<td>35-94</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td>MI acute</td>
<td>5,021</td>
<td>4,936-5,106</td>
<td>(32)</td>
<td></td>
</tr>
<tr>
<td>MI follow up (monthly)</td>
<td>97</td>
<td>55-150</td>
<td>(33)</td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>5,351</td>
<td>5,236-5,467</td>
<td>(34)</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia e</td>
<td>0.69</td>
<td>0.39-1.07</td>
<td>(26)</td>
<td></td>
</tr>
<tr>
<td>CTEPH acute</td>
<td>7,121</td>
<td>4,070-11,011</td>
<td>(35)</td>
<td></td>
</tr>
<tr>
<td>CTEPH follow up (monthly)</td>
<td>84</td>
<td>48-130</td>
<td>(35)</td>
<td></td>
</tr>
</tbody>
</table>

### Indirect costs

<table>
<thead>
<tr>
<th>Cost parameters</th>
<th>Average (2013, €)</th>
<th>Cost</th>
<th>Range</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Productivity loss age group 55-60 (per hour) g</td>
<td>31</td>
<td>17-47</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td>Productivity loss age group 60-65 (per hour) g</td>
<td>23</td>
<td>13-36</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td>ICH informal care mild (annually)</td>
<td>12,369</td>
<td>7,070-15,462</td>
<td>(36)</td>
<td></td>
</tr>
<tr>
<td>ICH informal care moderate (annually)</td>
<td>16,345</td>
<td>9,343-25,274</td>
<td>(36)</td>
<td></td>
</tr>
<tr>
<td>ICH informal care severe (annually)</td>
<td>20,322</td>
<td>11,616-31,422</td>
<td>(36)</td>
<td></td>
</tr>
</tbody>
</table>

VKA, vitamin K antagonists; LMWH, low molecular weight heparins; INR, international normalised ratio; MCRB, major or clinically relevant bleeding; DVT, deep vein thrombosis; PE, pulmonary embolism; CRNMB = clinically relevant non-major bleed event; ICH = intracranial haemorrhage; MB = major bleed; MI = myocardial infarction; UA, unstable angina; CTEPH = chronic thromboembolic pulmonary hypertension; PTS = post thrombotic syndrome GP, general practitioner.

<table>
<thead>
<tr>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>a Cost estimates that were available only as single point estimates, were assumed to follow a log-normal distribution with a coefficient of variation equal to 0.25.</td>
</tr>
<tr>
<td>b Travel costs of patients included only in the base-case.</td>
</tr>
<tr>
<td>c Assumed to be equal to the cost of a GP visit.</td>
</tr>
<tr>
<td>d Assumed to be equal to the cost of two GP visit.</td>
</tr>
<tr>
<td>e Assumed the cost of Omeprazol 20mg.</td>
</tr>
<tr>
<td>f Based on the study by Mayer et al, pulmonary endarterectomy is applied to 56.8% of cases.</td>
</tr>
<tr>
<td>g One hour of productivity loss costs was estimated as a weighted average cost for employed and non-employed population in the Netherlands in the specific age group.</td>
</tr>
</tbody>
</table>

### Sensitivity analyses

Univariate sensitivity analyses were performed to identify the key determinants of CE by varying parameters individually over the ranges derived from their 95% confidence intervals. Where confidence intervals and standard deviations of parameters were unavailable, the standard error was assumed to be 25% of the mean. The exceptions were...
made when varying discount rates which were varied between 0 and 5%, and the number of days on treatment with LMWHs which were varied between 5 and 9 days. The results were defined in terms of incremental cost per QALY and are presented diagrammatically in the form of a tornado diagram.

Additionally, a probabilistic sensitivity analysis (PSA) was performed to assess the robustness of the findings by performing 1,000 simulations to generate ICERs in which event risks and HRs, costs and utilities were simultaneously varied randomly within their ranges. HRs were sampled from a normal distribution on the log scale, probabilities were sampled from a beta distribution, and costs were sampled from a gamma distribution. For utilities, a gamma distribution was used, except for utilities assigned to DVT and PE, for which a normal distribution was used. Results from the PSA were plotted on a CE plane.

Scenario analyses

To investigate the impact of applying dabigatran under different decision making settings four scenario analyses were conducted. First scenario compared the use of dabigatran and VKAs for treatment and secondary prevention in high risk patients from the healthcare provider perspective. Second scenario compared the use of dabigatran to VKAs for up to 6 months of treatment only. Third scenario assessed the use of anticoagulants for up to 18 months of secondary prevention only (not considering the preceding treatment duration). In the fourth scenario, the use of dabigatran for up to 6 months of secondary prevention (not considering the preceding treatment duration) was compared to placebo. Here, study population simulated the profile of the patients in the RE-SONATE trial (i.e. patients for whom the need for secondary prevention is at equipoise (10)). Data from the RE-SONATE trial were the main sources used to estimate the transition probabilities between the health states in the model in this scenario.
RESULTS

Under base-case conditions, in a hypothetical cohort of 10,000 patients with VTE event followed over their lifetime starting at age 54.7 years, dabigatran averted 720 MCRBs compared with VKAs but resulted in an additional 86 rVTEs, and 65 MIs (Table 4). A comparable number of PTS, CTEPH and UA was observed in both dabigatran and VKAs treatment arms. Dabigatran was associated with a projected discounted quality-adjusted life expectancy of 19.187 QALYs compared with 19.129 QALYs for patients receiving VKAs. Costs allocation across different categories indicated that costs associated with handling rVTE, bleeding and other adverse events were the greatest contributors to the total expenditures. In VKAs treatment arm, these costs were higher compared to dabigatran arm (€12,409 vs €11,072). Expenditures for event-related costs were followed by monitoring and administration costs which were higher with VKAs compared to dabigatran (€3,730 vs. €1,242), and the total drug costs that were higher with dabigatran than VKAs (€1,549 vs. €298). Finally, accounting for all the aforementioned cost categories resulted in the total lifetime costs varied from €12,254 per person for VKAs to €10,258 per
person for dabigatran at a discount rate of 4%. In total, the savings of €1,996 and an additional 0.0583 discounted QALYs per patient where observed when applying dabigatran compared to VKAs (Table 5).

**Sensitivity analyses**
The results of univariate sensitivity analyses for the top 15 parameters by the order of influence they have to the ICERs are presented in the form of a tornado diagram (Figure 2). Specifically, the ICER was mostly influenced by variations in the probability of VTE-related death, productivity loss costs in the age group 55-60, probability of MCRBs-related and probability of ICH.
The results of 1,000 iterations in PSA are presented through an incremental CE plane in Figure 3. The probability that dabigatran is cost-effective at a willingness-to-pay (WTP) threshold of €20,000/QALY was 100%.

**Scenario analyses**
The results of the scenario analyses are presented in Table 5. In the scenario comparing dabigatran to VKAs for the treatment, and in the one comparing them for the secondary prevention in high-risk patients, dabigatran remained cost-saving. In the scenario comparing dabigatran to VKAs for treatment and secondary prevention from the healthcare provider perspective dabigatran was cost-effective with an ICER of €1,005 per QALY gained. Finally, the scenario examining the prevention of recurrent VTE in patients who are at equipoise for anticoagulation treatment with dabigatran compared to placebo, yielded an ICER of €33,305 per QALY gained.
Table 4 Recurrent VTE, bleeding complications and other adverse events and related costs within a hypothetical patient population of 10,000 subjects receiving dabigatran and VKA over a lifetime horizon.

<table>
<thead>
<tr>
<th>Event</th>
<th>Dabigatran Number of events</th>
<th>Costs p.p. (undiscounted)</th>
<th>VKA Number of events</th>
<th>Costs p.p. (undiscounted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index VTE</td>
<td>10,000</td>
<td>€2,142</td>
<td>10,000</td>
<td>€2,142</td>
</tr>
<tr>
<td>All recurrent VTE</td>
<td>13,471</td>
<td></td>
<td>13,384</td>
<td></td>
</tr>
<tr>
<td>Recurrent non-fatal VTE</td>
<td>11,959</td>
<td></td>
<td>11,871</td>
<td></td>
</tr>
<tr>
<td>Non-fatal DVT</td>
<td>8,761</td>
<td>€1,071</td>
<td>8,713</td>
<td>€1,065</td>
</tr>
<tr>
<td>Non-fatal PE</td>
<td>3,198</td>
<td>€1,592</td>
<td>3,158</td>
<td>€1,570</td>
</tr>
<tr>
<td>VTE-related death</td>
<td>1,512</td>
<td>€0</td>
<td>1,513</td>
<td>€0</td>
</tr>
<tr>
<td>All MCRBs</td>
<td>1,351</td>
<td></td>
<td>2,071</td>
<td></td>
</tr>
<tr>
<td>Non-fatal MCRBs</td>
<td>1,342</td>
<td></td>
<td>2,052</td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>28</td>
<td>€1,876</td>
<td>47</td>
<td>€3,262</td>
</tr>
<tr>
<td>Other MBs</td>
<td>230</td>
<td>€118</td>
<td>339</td>
<td>€177</td>
</tr>
<tr>
<td>CRNMBs</td>
<td>1,084</td>
<td>€9</td>
<td>1,665</td>
<td>€14</td>
</tr>
<tr>
<td>Deaths from bleeding</td>
<td>9</td>
<td>€0</td>
<td>19</td>
<td>€0</td>
</tr>
<tr>
<td>MI</td>
<td>86</td>
<td>€93</td>
<td>21</td>
<td>€23</td>
</tr>
<tr>
<td>UA</td>
<td>23</td>
<td>€23</td>
<td>23</td>
<td>€23</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>682</td>
<td>€0.05</td>
<td>112</td>
<td>€0.01</td>
</tr>
<tr>
<td>PTS</td>
<td>1,294</td>
<td>€3,482</td>
<td>1,290</td>
<td>€3,471</td>
</tr>
<tr>
<td>CTEPH</td>
<td>243</td>
<td>€667</td>
<td>242</td>
<td>€662</td>
</tr>
</tbody>
</table>

Medication

- Investigational treatment: €1,315, €24
- LMWHs, index event: €71, €110
- Re-treatment recurrent event, VKA: €12, €12
- Re-treatment recurrent event, LMWHs: €152, €152

Monitoring and administration

- INR-monitoring, GP visits, administration and productivity loss: €167, €2,622
- Index event: Administration of LMWHs: €43, €81
- Re-treatment with VKA for recurrent event: INR-monitoring, GP visits, administration and productivity loss: €901, €896
- Re-treatment recurrent event: Administration of LMWHs: €131, €130

VKA, vitamin K antagonists; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; r, recurrent; LMWH, low molecular weight heparin; CRNMB = clinically relevant non-major bleed event; ICH = intracranial haemorrhage; MB = major bleed; MI = myocardial infarction; CTEPH = chronic thromboembolic pulmonary hypertension; PTS = post thrombotic syndrome; UA, unstable angina; INR, international normalised ratio.
### Table 5 Results of the base-case and scenario analyses.

#### Base-case: 6 months treatment + 18 months secondary prevention (societal perspective)

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran</th>
<th>VKA</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted LYs</td>
<td>22.053</td>
<td>22.025</td>
<td>0.0282</td>
</tr>
<tr>
<td>Discounted QALYs</td>
<td>19.187</td>
<td>19.129</td>
<td>0.0583</td>
</tr>
<tr>
<td>Costs (€) undiscouned</td>
<td>13,865</td>
<td>16,437</td>
<td>-2,571</td>
</tr>
<tr>
<td>Costs (€) discounted</td>
<td>10,258</td>
<td>12,254</td>
<td>-1,996</td>
</tr>
<tr>
<td>ICER (€/ LYs)</td>
<td>Cost-saving</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICER (€/ QALYs)</td>
<td>Cost-saving</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Scenario 1: 6 months treatment + 18 months secondary prevention (healthcare provider perspective)

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran</th>
<th>VKA</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted LYs</td>
<td>22.053</td>
<td>22.025</td>
<td>0.0282</td>
</tr>
<tr>
<td>Discounted QALYs</td>
<td>19.187</td>
<td>19.129</td>
<td>0.0583</td>
</tr>
<tr>
<td>Costs (€) undiscouned</td>
<td>12,140</td>
<td>12,346</td>
<td>-206</td>
</tr>
<tr>
<td>Costs (€) discounted</td>
<td>9,067</td>
<td>9,008</td>
<td>59</td>
</tr>
<tr>
<td>ICER (€/ LYs)</td>
<td>2,078</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICER (€/ QALYs)</td>
<td>1,005</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Scenario 2: 6-months treatment (societal perspective)

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran</th>
<th>VKA</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted LYs</td>
<td>21.924</td>
<td>21.907</td>
<td>0.0170</td>
</tr>
<tr>
<td>Discounted QALYs</td>
<td>19.083</td>
<td>19.056</td>
<td>0.0266</td>
</tr>
<tr>
<td>Costs (€) undiscouned</td>
<td>12,219</td>
<td>13,461</td>
<td>-1,241</td>
</tr>
<tr>
<td>Costs (€) discounted</td>
<td>9,000</td>
<td>10,010</td>
<td>-1,010</td>
</tr>
<tr>
<td>ICER (€/ LYs)</td>
<td>Cost-saving</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICER (€/ QALYs)</td>
<td>Cost-saving</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Scenario 3: 18-months secondary prevention in high-risk patients (societal perspective)

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran</th>
<th>VKA</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted LYs</td>
<td>22.044</td>
<td>22.030</td>
<td>0.0144</td>
</tr>
<tr>
<td>Discounted QALYs</td>
<td>19.248</td>
<td>19.212</td>
<td>0.0368</td>
</tr>
<tr>
<td>Costs (€) undiscouned</td>
<td>10,297</td>
<td>11,755</td>
<td>-1,458</td>
</tr>
<tr>
<td>Costs (€) discounted</td>
<td>6,692</td>
<td>7,758</td>
<td>-1,066</td>
</tr>
<tr>
<td>ICER (€/ LYs)</td>
<td>Cost-saving</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICER (€/ QALYs)</td>
<td>Cost-saving</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Scenario 4: 6-months secondary prevention with placebo in patients for whom the need for secondary prevention is at equipoise (societal perspective)

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran</th>
<th>VKA</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted LYs</td>
<td>21.950</td>
<td>21.950</td>
<td>0.0003</td>
</tr>
<tr>
<td>Discounted QALYs</td>
<td>19.169</td>
<td>19.165</td>
<td>0.0035</td>
</tr>
<tr>
<td>Costs (€) undiscouned</td>
<td>7,971</td>
<td>7,873</td>
<td>98</td>
</tr>
<tr>
<td>Costs (€) discounted</td>
<td>4,940</td>
<td>4,823</td>
<td>117</td>
</tr>
<tr>
<td>ICER (€/ LYs)</td>
<td>428,158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICER (€/ QALYs)</td>
<td>33,305</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VKA, vitamin K antagonists; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; LY, life year.
Figure 2 Tornado diagram illustrating ICERs from sensitivity analyses for dabigatran vs. vitamin-K antagonists.

Figure 2 presents a tornado diagram illustrating the impact of varying each of input parameters on the ICER while holding all the other model parameters fixed. Light grey bars denote influence of the high limit and dark grey bars denote influence of the low limit of the input parameters investigated on the ICER. The solid vertical line represents the base case incremental costs per QALY for dabigatran compared to VKA. Horizontal bars indicate the range of incremental costs per QALY obtained by setting each variable to the values shown while holding all other values constant.

ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; VKA, vitamin K antagonists; VTE, venous thromboembolism; r, recurrent; ICH = intracranial haemorrhage; MBE = major bleeding event; HR, hazard ratio.

Figure 3 Incremental cost-effectiveness plane.
DISCUSSION

Our base-case decision analysis demonstrated dabigatran may be a cost–saving alternative to VKAs for the treatment and secondary prevention of VTE from societal perspective. Patients on dabigatran gained an additional 0.583 discounted QALYs over a lifetime and savings of €1,996. The key drivers of the CE of dabigatran relative to trial-based VKA are based on its ability to reduce MCRBs as found in RECOVER trials. Particularly, the use of dabigatran resulted in 710 less MCRB events (i.e. 19 ICHs, 109 other MBs and 582 CRNMBs) in a cohort of 10,000 patients.

Results were sensitive to the probability of VTE-related death, productivity loss costs, probability of MCRBs-related death and probability of ICH, yet, they all indicated dabigatran to be cost-saving compared to VKAs. Moreover, the PSA showed that the likelihood of dabigatran being cost-effective at WTP threshold of €20,000 per QALY was 100%.

The results of the scenario analyses comparing dabigatran to VKAs for the treatment, secondary prevention in high-risk patients, were quite robust, all indicating dabigatran may be cost-saving alternative to VKAs. However, in the scenario examining the CE of anticoagulants for the treatment and secondary prevention from the healthcare provider perspective, dabigatran was shown to be a cost-effective alternative to VKAs with an ICER of €1,005 per QALY gained. Interestingly, although the variability in productivity loss costs showed an impact on the estimated ICER in the univariate sensitivity analyses, excluding these costs together with other indirect costs still led to highly cost-effective findings in the aforementioned scenario. Finally, in the scenario examining the prevention of recurrent VTE in patients who are at equipoise for anticoagulation treatment, unlikely to be treated with anticoagulants in clinical practice, dabigatran was found to be cost-effective compared to placebo with an ICER of €33,305 per QALY gained. This finding reflects the higher total costs associated with greater number of MCRBs and drug costs in dabigatran treatment arm compared to placebo arm.

To our knowledge, this is the first study that examined the use of dabigatran compared to VKAs for the treatment and prevention of VTE in the Dutch setting. In terms of the economic consequences of using dabigatran compared to VKAs, our findings are similar to the ones by Braidy et al (37). A cost-minimisation analysis by Braidy et al. investigated the use of NOACs and VKAs for the prevention of VTE and stroke in patients with atrial fibrillation from the third-party payer perspective in Australian setting (37). They found dabigatran to be dominant over VKA ($AUS40) in terms of cost of drug administration and therapeutic monitoring. Notably, a direct comparability between the two studies is hampered due to differences in the underlying patients’ characteristics, safety and effectiveness data used, country-specific cost estimates and study perspective.
Our study is confronted with several potential limitations. One limitation might be that the duration of initial treatment with LMWHs was assumed to be different in dabigatran and VKAs treatment arms in the base-case analysis (i.e. 5 and 9 days respectively). However, the duration of treatment with LMWHs was assumed to have no impact on the effectiveness of the follow up use of dabigatran and VKAs. To cope with this limitation, we varied the duration of LMWHs treatment between 5 and 9 days for both treatment alternatives in univariate sensitivity analyses. The results remained robust to variability in the duration of LMWHs use. Furthermore, this study simulated the occurrences of all MCRBs further subdivided into ICHs, other MBs and CRNMBs, however, the meta-analysis of the RE-COVER trials indicated that there was only a marginally significant reduction of MBs observed in the double-dummy period in dabigatran arm compared to VKA. Therefore, simulating the occurrences of MBs might overestimate the benefits in the dabigatran arm compared to VKA. Similarly, acute coronary syndromes (i.e. MIs and UAs) were modelled in this study although their incidence was only numerically higher with dabigatran compared to VKAs. A further potential limitation in our study concerns the assumption that patients in both treatment arms who experience a first recurrent VTE event would switch to a 6-months standard treatment course of LMWH followed by VKAs. This may not always be the case and patients might alternatively be switched to other NOACs. However, there are currently no available efficacy and safety data that could characterize such a switch. Furthermore, a maximum of two rVTEs over the lifetime of the patients and two MBs during the anticoagulation treatment were modelled. This assumption may be considered conservative given that a better safety profile of dabigatran treatment would be associated with a lower number of MBs and consequent lower costs compared to treatment with VKAs. Another limitation concerns treatment discontinuation that was assumed for patients who experience a MB or ICH. In a real-life setting such a decision would likely be based on individual patient characteristics. Finally, given the lack of specific treatment recommendations for patients experiencing CRNMBs, the discontinuation of treatment due to CRNMB was not modelled. Notably, in daily practice, patients may discontinue with the treatment after a certain number of consequent CRNMBs.

In conclusion, from a societal perspective, this modelling study suggests that the use of dabigatran for treatment and secondary prevention of VTE is maximally likely to be a cost-effective alternative to VKAs at a WTP threshold €20,000 per QALY in the Dutch setting. Importantly, even when the comparison between dabigatran and VKAs was assessed from the healthcare provider perspective, dabigatran remained highly cost-effective with an ICER of €1,005 per QALY gained.

In addition to some established advantages of dabigatran (e.g. better safety profile than VKAs; excludes the need for INR-monitoring), our study estimated the long-term economic benefits associated with its use. Yet, it must be acknowledged that such benefits in a “real
life” setting are still to be proven. Notably, given that dabigatran is the second NOAC registered in Europe for the treatment and secondary prevention of VTE, further investigation is needed to estimate comparative effectiveness and CE among the individual NOACs.

Acknowledgment
This study was funded with a grant by Boehringer Ingelheim. The authors declare study results were not influenced by this funding.
REFERENCES


(26) Z-index WMG-geneesmiddelen. , 2014.


